Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

Twist Bioscience FY 2026 Results: Net Loss of $130M, Loss Widens

Twist Bioscience reported net proceeds of approximately $327.7 million from an August 2026 public offering and $97.1 million from an at-the-market program. Despite these capital raises, the company anticipates continued net losses and negative free cash flows for the near future while expanding international operations, which accounted for 41% of revenue in fiscal 2026.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Revenue459.4376.6
Profit before tax-129.8-77.0
Net income-130.2-77.7
EPS (diluted, $ a share)$-2.08$-1.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+22.0%
Operating margin-30.4%
Source

10-K filed with the SEC, NASDAQ: TWST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Twist Bioscience Corp: key numbers

Share price
$105.04Close, Nov 16
Market cap
$7.16B
Shares outstanding
68.18MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Twist Bioscience Corp

All →
7:20 AM ET 8-K
Financial Results

Twist Bioscience Financial Results

Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.

Term
FY2026

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
4:06 PM ET Form 4
Insider Selling

Twist Bioscience Insider Dennis Cho Sells $128K of Stock

Dennis Cho sold 949 shares of Twist Bioscience Corp at $135.40 a share, worth $128K in total on Nov 3, 2026. Shares held after the trade: 62,840 (-1.5%).

Value
$128K
Shares
949
Price
$135.40
Holding change
-1.5%
Trade date
Nov 3, 2026
4:05 PM ET Form 4
Insider Selling

Twist Bioscience SVP of Human Resources Paula Green Sells $136K of Stock

Paula Green, SVP of Human Resources, sold 1,007 shares of Twist Bioscience Corp at $135.40 a share, worth $136K in total on Nov 3, 2026. Shares held after the trade: 105,625 (-0.9%).

Value
$136K
Shares
1,007
Price
$135.40
Role
SVP of Human Resources
Holding change
-0.9%
Trade date
Nov 3, 2026
4:05 PM ET Form 4
Insider Selling

Twist Bioscience CEO Emily M. Leproust Sells $619K of Stock

Emily M. Leproust, CEO, sold 4,573 shares of Twist Bioscience Corp at $135.40 a share, worth $619K in total on Nov 3, 2026. Shares held after the trade: 558,187 (-0.8%).

Value
$619K
Shares
4,573
Price
$135.40
Role
CEO
Holding change
-0.8%
Trade date
Nov 3, 2026
4:05 PM ET Form 4
Insider Selling

Twist Bioscience CAO Robert F. Werner Sells $20K of Stock

Robert F. Werner, CAO, sold 148 shares of Twist Bioscience Corp at $135.40 a share, worth $20K in total on Nov 3, 2026. Shares held after the trade: 42,769 (-0.3%).

Value
$20K
Shares
148
Price
$135.40
Role
CAO
Holding change
-0.3%
Trade date
Nov 3, 2026
4:05 PM ET Form 4
Insider Selling

Twist Bioscience President and COO Patrick John Finn Sells $347K of Stock

Patrick John Finn, President and COO, sold 2,565 shares of Twist Bioscience Corp at $135.40 a share, worth $347K in total on Nov 3, 2026. Shares held after the trade: 180,278 (-1.4%).

Value
$347K
Shares
2,565
Price
$135.40
Role
President and COO
Holding change
-1.4%
Trade date
Nov 3, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.